## European Directorate for the Quality of Medicines &HealthCare Europe





COUNCIL OF EUROPE

European Directorate | Direction européenne for the Quality | de la qualité of Medicines | du médicament & HealthCare | & soins de santé | C



# Fight against the counterfeiting of medicinal products in the OMCL Network

https://www.edgm.eu/en/testing-of-falsified-/-illegal-medicines

Marta Miquel (EDQM-ICND)



COUNCIL OF EUROPE





## **OMCL = Official Medicines Control Laboratory**

- OMCLs are public institutions which support (or are part of) regulatory authorities in controlling the quality of medicinal products for human and veterinary use (preauthorisation phase and/or post-marketing phase)
- OMCLs test medicinal products independently from manufacturers

**OMCL is a recognised term in the EU legislation** 











for the Quality of Medicines & HealthCare | & soins de santé

## **OMCL NETWORK (GEON)**

- Devised in 1994 by the EU Commission & CoE
- To promote the collaboration of OMCLs across Europe (and beyond) in the area of quality control of marketed medicinal products for <u>human</u> and <u>veterinary</u> use
- Set up in 1995 by the EDQM
- Network activities are co-financed by the EC (on basis of a contribution agreement)
- 68 members from 42 countries

#### https://www.edqm.eu/en/omcl-network

 Annual work programmes decided together with National Competent Authorities (NCAs) and the European Medicines Agency (EMA)

 EDQM: Secretariat and co-ordination of the Network activities and joint <u>surveillance programmes</u>

with General European OMCL Network







## **GEON Composition\***

- **26** out of the 27 EU countries (except Malta)
- 7 European non-EU countries: Bosnia & Herzegovina, Republic of Moldova, Republic of North Macedonia, Serbia, <u>Türkiye</u>, Ukraine, United Kingdom
- Norway (EEA) & Switzerland (MRA)
- **7** non-European partners (Australia, Canada, Israel, Kazakhstan, Morocco, Singapore and Taiwan FDA): associate members as observers to Ph. Eur. Convention







### **Creation of the Falsified Medicines WG**



- Early 2000s: many OMCLs analysing falsified/illegal medicines on behalf of customs, police, health authorities, inspectors, courts => authenticity testing and screening for unknown products.
- 2005: decision taken by the OMCL Network to better coordinate the work of the individual OMCLs in the field of falsified/illegal medicines testing.
- October 2006: <u>Data repository</u> set up by the EDQM to post test reports, facilitating a rapid exchange of information on testing activities in the field of falsified medicines. March 2014: replaced by the Know-X database.
- Since 2007: the EDQM organises the programme "Suspicious Unknown Products" (SUP). The aim is to evaluate whether the OMCLs are able to <u>identify</u> (and, where possible, <u>quantify</u>) unknown active pharmaceutical ingredients (APIs) in a "blind" sample.
- December 2010: adoption of <u>MEDICRIME</u> convention by Committee of Ministers of the Council of Europe.
- June 2011: <u>DIRECTIVE 2011/62/EU</u> of the European Parliament and of the Council, relating to the prevention of the entry into the legal supply chain of falsified medicinal products.
- 2011: creation of the Falsified Medicines WG of the OMCL Network.







#### How the OMCL Network supports the NCAs in the implementation of MEDICRIME ? Document available on the EDQM website <u>here</u>

- Article 17 National measures of co-operation and information exchange => the OMCL Network uses IT
  platforms that facilitate a rapid dissemination of information; OMCLs collaborate with customs, police and other
  governmental agencies at national level.
- Article 18 Preventive measures e.g. take the necessary legislative and other measures to establish the quality and safety requirements of medical products => OMCLs help NCAs monitoring the quality and safety of medicines (whether PRE or POST marketing) & active substances.
- Article 22 => international co-operation on prevention and other administrative measures => Networking is a key element for OMCLs for an effective co-operation at international level: exchange of information, training activities, regular meetings, collaborative programmes, mutual assistance, etc.
- Article 25 => the Committee of Parties (CoP) should monitor the implementation of the Convention => the EDQM is represented in the CoP => facilitates communication between the CoP and the OMCL Network.



OMCLs are explicitly mentioned in the Explanatory Report to the Medicrime convention of the Network of Medicines & HealthCare & Swins de



#### **OMCL Network Falsified Medicines WG**

- General European OMCL. Network
- The OMCL Network FM WG was established in 2011 with the aim of reinforcing the collaboration between OMCLs in the field of testing of falsified/illegal medicines, to foster a coordinated approach and to draw up a work programme.
- The WG is composed of representatives from 24 OMCLs and they meet twice per year.

#### Work programme of the FM WG:

- Exchange of information related to analysis on suspect samples:
  - Via IT platforms (Know-X) and regular meetings (2/year)
  - Contacts with other Authorities in the same field (e.g. customs labs, enforcement officers, etc)
- Identification of training needs: hands-on training sessions and SUP studies.
- Market surveillance programmes (MSS) on falsified and illegal products:
  - MSSIP: Market Surveillance on Suspected Illegal Products
  - MSSFP: Market Surveillance Study Type FingerPrint
- Know-X database: assistance with its establishment, maintenance and further development.



#### Fight against Falsified Medicines in the GEON – Key Principles



#### 1. Data Pooling



#### Know-X Database

- Exchange of information in the field of falsified medicinal products and similar crimes.
- Allows issuing <u>Rapid Alerts</u>, observance of <u>trends</u>, encourages <u>collaboration</u> between stakeholders, sharing of <u>analytical</u> information, etc.
- In 2024, 293 cases were reported by OMCLs in Know-X, of which183 concerning anabolic steroids.

<u>MSSIP</u> – <u>Market</u> <u>Surveillance</u> Studies on <u>Suspected</u> <u>Illegal</u> <u>P</u>roducts

- 7 finalised, 1 ongoing
- MSSIP focus on specific product groups e.g. slimming food supplements, sexual potency enhancers, anabolic steroids, etc.
- Conclusions shared :
  - with all OMCLs of the OMCL Network
  - published on EDQM website
  - reported in Know-X
  - sent to the EU Commission
  - publication in scientific journals.

#### <u>MSSFP</u> – <u>Market</u> <u>Surveillance</u> <u>Studies</u> – type <u>Fingerprint</u>

- 5 finalised, 1 ongoing
- MSSFP focus on **API testing**: quality + authenticity of sources.
- Conclusions shared as above.





European Directorate Direction for the Quality de la qual of Medicines du médici & HealthCare & soins de

# Market Surveillance Studies on Suspected Illegal Products (<u>MSSIP</u>)





- Focus on specific product groups e.g. slimming food supplements, sexual potency enhancers, anabolic steroids.
- Collection of **retrospective and prospective data**, over a defined period of time.
- The objective is to map the extent of the presence of such products in member states of the OMCL
   Network and to raise awareness of this phenomenon to public and the EU Commission.
- Participating OMCLs sample the products directly on their own (from pharmacies, herbal shops, gyms, internet, etc) or receive them via inspectors/customs/police, then analyse them with the analytical methods of their choice.

Conclusions/results:

- Shared within the whole OMCL Network.
- Published on EDQM website.
- Reported in **Know-X** by the participating OMCL.
- Shared with the EU Commission (final report).
- Published in scientific journals. For example: MSSIP005 <u>The occurrence of non-anatomical</u> <u>therapeutic chemical-international non-</u> <u>proprietary name molecules in suspected illegal</u> <u>or illegally traded health products in Europe: A</u> <u>retrospective and prospective study</u>, 2021, doi: 10.1002/dta.3001.





#### MSSIP (cont.)

MSSIP006 on SARMs, Metabolic Modulators and small molecule Growth Hormone Secretagogues used as Performance Enhancir substances.

- **14** participating OMCLs.
- Scientific Advisor: Magnolia Mendoza Barrios (AEMPS, Spain)
- 324 samples.
- Final Report available online.
- Report sent to the <u>EU Commission</u> in January 2024.
- Status: scientific article drafted under review by OMCLs.

#### **MSSIP007** on Nootropics

- 12 participating OMCLs
- Scientific Advisors: Eric Deconinck and Céline Vanhee (Sciensano, Belgium).
- 159 samples.
- Products in scope: natural, semi-synthetic and synthetic nootropics.
- <u>Status</u>: Finalised Draft report under review by the OMCLs.
- Scientific article under preparation.



#### Top 3 reported molecules:

- melatonin (33)
- modafinil (25)
- levodopa (L-Dopa) (21)









#### MSSIP (cont.)

**MSSIP008** on Antibiotics from illegal sources

- Scientific Advisor: Andreas Blomgren (MPA, Sweden).
- 8 registered OMCLs.
- Objective: to identify any deviation from label claim of the products, with focus on API identity, and to raise awareness of the problems concerning self-diagnosis and self-medication using antibiotics.
- Status: Ongoing. No results collected yet.
- Timeframe: January 2024 to September 2025.

- **Proposals for future MSSIPs**:
- Anaesthetic creams containing lidocaine or similar APIs
- Melatonin
- GLP-1 receptor agonists
- Abortion pills
- HIV prophylactic medicines
- Botox





Aedicines | du médicamen

## MSS on Suspected Illegal Products - MSSIP



COUNCIL OF FUR

HealthCare | & soins de sante



#### Fight against Falsified Medicines in the GEON – Key Principles (cont.)



#### 2. Competence Pooling



	OMCL Inventory Database	Exception for the second secon						
Home OMCL Competences Users Forum Admin -								
Welcome to OMCL Inventory Database								
Official Medicines Control Laboratories								
The OMCL Inventory Database is a dedicated tool for members of the GEON to share reliable first-hand information about the general organisational structure, the QMS status and the competencies of their OMCL.								
It is restricted to full, associate and limited members of the GEON.								
Further information about the GEON membership and activities can be found on the EDQM web site: https://www.edqm.eu/en/general-european-omcl-network-geon								

OMCL

Export +

Home

#### **OMCL Inventory Database**

 The OMCL Inventory Database is a tool to share information about the analytical competences of OMCLs => OMCLs not having specific competences/equipment to perform certain tests can send samples to another OMCL.

#### List of competences

Competences

Users

Forum

Admin -

	I	Туре	Method	Sub method	Competence level	Frequency level	Run Acc Ph.Eur.	QMS/Prog	Spec
Show obsolete Competences	BIO	Total protein	Method 1 (Aromatic amino acids assay)	4	E	True	QMS		
	BIO	Bacterial endotoxins (LAL)	Method A (Gel-clot limit test)	2	С	True	PTS/OCABR/ QMS	Ρ	
	ВЮ	BIO	Antigenicity	UV-Vis absorption spectrophotometry	1	A	False	QMS	
		BIO	Cell-culture/cell-line based assay	50% cell culture infective dose (CCID50)	2	A	True	QMS	





#### 3. Training and Know-how Exchange

## Symposia on combating falsified and other illegal medicines

4 symposia organised since 2011, each with around 100 participants. 5<sup>th</sup> Symposium will be held in June 2026 in Prague. Hosted by the Czech OMCL SUKL.

**Bring together stakeholders** working in the field of falsified/illegal medicines: OMCLs, health authorities, police, forensic laboratories, customs and the European Commission. <u>Press Releases</u>

Hands-on training sessions (20 since 2012)

• **Practical technical training** of OMCL personnel by partner OMCLs experienced in certain techniques.

#### SUP – <u>S</u>uspicious <u>U</u>nknown <u>P</u>roduct Test Programme

- 14 finalised, 1 ongoing.
- Similar to a Proficiency Test Scheme (PTS).
- The aim is to test the competency of the laboratories to <u>identify</u> the active ingredient in an unknown sample.
- Use of **blind** samples: commercially available medicines and APIs or real falsified/illegal samples
- Participants: 25 30 OMCLs.

#### Joint meetings with other stakeholders

- **CLEN** (Customs Laboratories European Network)
- WGEO (Working Group of Enforcement Officers)
- **CMED** (Committee of Experts on minimising the public health risks posed by falsified medical products and related crimes)





## Hands-on training sessions for OMCLs





Cell-based potency assay testing of mAbs Host: OMCL INFARMED, Lisbon, PT 31 March to 3 April 2025 7 participants

Peptide and protein testing Host: OMCL Sciensano, Brussels, BE 5 to 7 May 2025 7 participants 202 6

Falsified/Illegal Medicines Testing Host: OMCL National Medicines Institute, Warsaw, PL April 2026 Training in 3 techniques: 1. LC-HRMS, 2. XRPD, 3. NMR 15 participants

Date to be confirmed: Falsified/Illegal Medicines Testing Host: Medical Products Agency, Uppsala, SE A general approach for analysing unknown samples using LC–QTOF-MS/MS and NMR spectroscopy





#### Fight against Falsified Medicines in the GEON – Key Principles (cont.)



#### 4. Targeted Communication

#### **Documents**

- How the OMCL Network supports the implementation of the Council of Europe MEDICRIME Convention
- An "aide-mémoire" for the testing of suspected illegally traded and falsified medicines
- <u>Aide-Mémoire: How to identify a Falsified</u> <u>Monoclonal Antibody / Antibody containing</u> <u>Fusion Protein</u>
- Council of Europe Convention on the Counterfeiting of Medical Products and Similar Crimes involving Threats to Public Health (or MEDICRIME Convention)

#### **Publications**

- <u>The occurrence of non-anatomical therapeutic chemical-</u> international non-proprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study, doi: 10.1002/dta.3001 (2021).
- European fingerprint study on omeprazole drug substances using a multi analytical approach and chemometrics as a tool for the discrimination of manufacturing sources; Journal of Pharmaceutical and Biomedical Analysis, Vol. 208 (2022) (10.1016/j.jpba.2021.114444)
- <u>GEONs API fingerprint project: Selection of analytical techniques</u> for clustering of sildenafil citrate API samples; Talanta, Vol. 239 (2022) (10.1016/j.talanta.2021.123123)
- <u>Clustering of Tadalafil API Samples According to their</u> <u>Manufacturer in the Context of API Falsification Detection</u>; Journal of Pharmaceutical Sciences, Vol. 112 (2023) (10.1016/j.xphs.2023.05.015)





## For more information on the GEON...



#### Please consult the section "OMCL Network" on www.edqm.eu



#### More information





#### Follow us on

in <u>edqm</u>



X @edqm\_news







#### COUNCIL OF EUROPE

European Directorate Direction européenne for the Quality de la qualité of Medicines du médicament & HealthCare & soins de santé

